Beckman Coulter Wins CE Mark for 20-Minute Test Distinguishing Bacterial vs Viral Infections

Beckman Coulter Diagnostics received CE marking in April 2026 for a rapid diagnostic assay capable of distinguishing between bacterial and viral infections in approximately 20 minutes.

The development represents a significant advancement in rapid diagnostic testing, aimed at improving clinical decision-making and reducing unnecessary antibiotic use in healthcare settings.

Rapid Results Improve Clinical Decision-Making

The assay delivers results in just 20 minutes, compared to traditional diagnostic methods that can take hours or days.

• Faster diagnosis in emergency settings
• Immediate treatment decisions
• Reduced diagnostic uncertainty

Quick differentiation between infection types is crucial, as bacterial and viral infections often present with similar symptoms, making clinical diagnosis challenging.

Reducing Antibiotic Misuse and Resistance

The new assay plays a key role in addressing antimicrobial resistance, a growing global health concern.

• Prevents unnecessary antibiotic prescriptions
• Supports antimicrobial stewardship programs
• Helps preserve antibiotic effectiveness

Since antibiotics are only effective against bacterial infections, accurate diagnosis is essential to avoid misuse and slow resistance development.

CE Marking and Regulatory Importance

The CE mark confirms that the assay meets European Union safety and performance standards, allowing its use across EU markets.

• Validated clinical performance
• Compliance with regulatory requirements
• Enables adoption in hospitals and labs

This approval marks a key milestone in bringing advanced diagnostic tools into routine clinical practice.

Impact on Healthcare Systems

Rapid infection testing can significantly improve healthcare efficiency and patient outcomes.

• Earlier treatment initiation
• Reduced hospital stays
• Lower healthcare costs

It also helps reduce unnecessary testing and hospital admissions, especially in high-pressure environments like emergency departments.

Advancing Diagnostic Innovation

The assay reflects broader innovation in clinical diagnostics, where fast and accurate testing is becoming essential for modern healthcare.

Key advancements include the following:

• Point-of-care diagnostic technologies
• Improved biomarker detection
• Data-driven clinical decision support

Such innovations are critical in addressing global health challenges, including infectious diseases and antimicrobial resistance.

The CE-marked assay represents a major step forward in aligning diagnostic capabilities with real-world clinical needs.

FAQs

What is the Beckman Coulter 20-minute test?

It is a rapid diagnostic assay that distinguishes between bacterial and viral infections within 20 minutes.

Why is this test important?

It helps doctors make faster treatment decisions and reduces unnecessary antibiotic use.

What does CE marking mean?

It indicates that the product meets European Union standards for safety, quality, and performance.

How does this help fight antibiotic resistance?

By accurately identifying infection type, it prevents misuse of antibiotics, slowing resistance development.